medigraphic.com

2012, Number 5

<< Back Next >>

Rev Fac Med UNAM 2012; 55 (5)

Multiple Sclerosis, a review of the literature

Domínguez MR, Morales EM, Rossiere ENL, Olan TR, Gutiérrez MJL

Language: Spanish
References: 20
Page: 26-35
PDF size: 247.81 Kb.


ABSTRACT

Multiple sclerosis is an autoimmune disease that affects the central nervous system, most common in young people aged 20-50 years. It is the leading cause of disability in this group. The clinical course is usually characterized by severe neurological afflictions followed by remissions and in some cases tend to be progressive to death. The diagnosis is based on clinical symptoms and is supported by the evidence of MRI lesions disseminated in time and space, multiple treatments are currently incapable of curing the disease but they are able to suppress outbreaks in great measure. This review was made with the mere objective to demonstrate the general spectrum of this wide illness with the idea that it is helpful to physicians and students who are not familiar with the disease that is becoming increasingly common in our country.


REFERENCES

  1. Murray TJ. Multiple Sclerosis: the history of a disease. J R Soc Med. 2005;98:289.

  2. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008; 7:268-77.

  3. Hawker K, Frohman E. Multiple Sclerosis. Prim Care Clin Office Pract. 2004;31:201-26.

  4. Sandovnick AD, Baird PA, Ward RH. Multiple sclerosis: updated risks for relatives. Am J Med Genet. 1988; 29:533-41.

  5. Kurtzke JF, Beebe GW, Norman JE. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology. 1979;29:1228-35.

  6. Nicot AB. Gender and sex hormones in multiple sclerosis pathology and therapy. Front Biosci. 2009;14:4477-515.

  7. Noseworthy J, Luccinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938-52.

  8. Fox E. Immunopathology of multiple sclerosis. Neurology. 2004;63.

  9. Izquierdo G, Ruiz Peña JL. Evaluación clínica de la esclerosis múltiple: cuantificación mediante la utilización de escalas. Rev Neurol. 2003;36:145-52.

  10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-52.

  11. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:525-7.

  12. Ruiz García D, Solar Salaberry LA. Esclerosis múltiple. Revisión bibliográfica. Rev Cubana Med Gen Integr. 2006; 22:1-11.

  13. Courtney AM, Treadaway K, Remington G, et al. Multiple Sclerosis. Med Clin N Am. 2009;93:451-76.

  14. Fox RJ, Bethoux F, Goldman MD, et al. Multiple sclerosis: Advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med. 2006;73:91-102.

  15. Velázquez M, López-Prieto, Márquez JC, et al. Características epidemiológicas de la esclerosis múltiple en un estado fronterizo con los Estados Unidos de Norteamérica. Arch Neurocien. 2002;7:147-50.

  16. Goodin DS, Frohman EM, Garmany GP. Disease modifying therapies in multiple sclerosis. Neurology. 2002;58: 169-78.

  17. Frohman EM. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics. 2007; 4(4):618-26.

  18. Schapiro TA. Managing Symptoms of Multiple Sclerosis. Neurol Clin. 23 2005:177-87.

  19. Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology. 1992;42:991-4.

  20. Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74:2004-15.




2020     |     www.medigraphic.com